Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Breast cancer, metastatic 1

LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer


19 Sep 2020


Proffered Paper - Breast cancer, metastatic 1



Tumour Site

Breast Cancer


Leisha Emens


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


L.A. Emens1, S. Adams2, C.H. Barrios3, V.C. Dieras4, H. Iwata5, S. Loi6, H.S. Rugo7, A. Schneeweiss8, E.P. Winer9, S. Patel10, V. Henschel11, A. Swat12, M. Kaul13, L. Molinero14, S.Y. Chui15, P. Schmid16

Author affiliations

  • 1 Medicine/hematology-oncology Department, UPMC Hillman Cancer Center, 15232 - Pittsburgh/US
  • 2 Nyu School Of Medicine, NYU Langone Medical Center, New York/US
  • 3 Investigation Center, Hospital Sao Lucas da PUCRS, 90610-000 - Porto Alegre/BR
  • 4 Medical Oncology, Centre Eugène Marquis, 35042 - Rennes/FR
  • 5 Breast Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 6 Translational Breast Cancer Genomics Lab, Division Of Research, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 7 Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 8 German Cancer Research Center, University Hospital Heidelberg, 69115 - Heidelberg/DE
  • 9 Medicine, Dana Farber Cancer Institute, 2115 - Boston/US
  • 10 Medical Oncology, Genentech, 94080 - South San Francisco/US
  • 11 Biostatistics, Genentech, 94080 - South San Francisco/US
  • 12 Clinical Science, F. Hoffmann-La Roche, 4070 - Basel/CH
  • 13 Cancer Immunotherapy Clinical Safety, F Hoffman Roche, Basel/CH
  • 14 Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 15 Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 16 Barts Cancer Institute, Queen Mary University London, EC1M 6BQ - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract LBA16


Based on findings from IMpassion130, international guidelines now recommend atezolizumab (A) + nab-paclitaxel (nP) for patients (pts) with locally advanced or metastatic TNBC (mTNBC) whose tumours express PD-L1 on tumour-infiltrating immune cells (IC). Here we report prespecified final OS and long-term safety results.


The study design and final PFS analysis have been reported (Schmid NEJM 2018). Pts were randomised 1:1 to A + nP or placebo (P) + nP. Co-primary endpoints were PFS (tested in parallel in ITT and PD-L1+ pts) and OS (tested hierarchically in ITT and, if significant, in PD-L1+ pts).


As of 14 April 2020, 666/902 pts (73.8%) had died; median OS follow-up was 18.8 mo (IQR, 8.9-34.7 mo). 6% of pts in the A + nP arm and 2% in the P + nP arm remained on any treatment. OS data are in the Table. 460 A + nP arm pts and 430 P + nP arm pts were safety evaluable, of whom 8% and 3%, respectively, received nP for up to 24 mo. Similarly, 5% in the A + nP arm received nP for ≥ 24 mo (vs 1% in the P + nP arm). Respectively, 51% vs 43% had a G 3-4 AE; ≈ 1% per arm had a G 5 AE (no new G 5 AEs since last analysis; no patterns seen); 24% vs 19% had a serious AE, and 59% vs 42% had an AE of special interest (G 3-4 in 8% vs 5%). No confirmed or suspected COVID-19 AEs were reported. 19% in the A + nP arm and 8% in the P + nP arm had an AE leading to treatment discontinuation (most commonly due to neuropathy); in 18% and 8%, respectively, AEs led to nP discontinuation, and in 8% and 1%, AEs led to A or P discontinuation.


While OS differences for A + nP vs P + nP in the IMpassion130 ITT population were not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed in PD-L1+ pts (7.5-mo median OS improvement). A + nP remained safe and tolerable with longer follow-up. Results from this final and mature OS analysis are consistent with prior interim analyses. Table: LBA16

Final OS analysis A + nP (n = 451) P + nP (n = 451)
ITT population
Events, n (%) 322 (71) 344 (76)
Median OS (95% CI), mo 21.0 (19.0, 23.4) 18.7 (16.9, 20.8)
Stratified OS HRa (95% CI); log-rank P 0.87 (0.75, 1.02); 0.0770b
3-year OS (95% CI), % 28 (24, 32) 25 (21, 29)
PD-L1+ population c (n = 185) (n = 184)
Events, n (%) 120 (65) 139 (76)
Median OS (95% CI), mo 25.4 (19.6, 30.7) 17.9 (13.6, 20.3)
Stratified OS HR (95% CI) 0.67 (0.53, 0.86)d
3-year OS (95% CI), % 36 (29, 43) 22 (16, 28)

a Stratification factors: prior taxane use, liver metastases, PD-L1 status. b Not significant c PD-L1 positivity defined as PD-L1–stained IC on ≥ 1% of the tumour area (VENTANA SP142 IHC assay) d Not formally tested per prespecified testing hierarchy.

Clinical trial identification


Editorial acknowledgement

Medical writing assistance for this abstract was provided by Ashley J. Pratt, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.


F. Hoffmann-La Roche, Ltd.


L.A. Emens: Honoraria (self): AbbVie, Amgen, Celgene, Chugai, Gritstone, MedImmune, Peregrine, Shionogi, Syndax; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca, Bayer, MacroGenics, Replimune, Vaccinex; Travel/Accommodation/Expenses: Bristol Myers Squibb, Genentech/Roche, Novartis; Research grant/Funding (institution): Aduro Biotech, AstraZeneca, The Breast Cancer Research Foundation, Bristol Myers Squibb, Bolt Therapeutics, Corvus, The US Department of Defense, EMD Serono, Genentech, Maxcyte, Merck, The National Cancer Institute, The NSABP Foundation, Roche, The Transl; Licensing/Royalties: Aduro; Advisory/Consultancy: Roche. S. Adams: Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Merck, Amgen, BMS, Novartis, Celgene, Daiichi Sankyo. C.H. Barrios: Advisory/Consultancy: Boehringer- Ingelheim; Advisory/Consultancy: GSK; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/ Consultancy, Research grant/Funding (institution): Roche/Genentech; Advisory/Consultancy: Eisai; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Non-remunerated activity/ies: Bayer; Research grant/ Funding (institution): AbbVie; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Medivation; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Taiho Pharmaceutical; Research grant/Funding (institution): Mylan; Research grant/Funding (institution): Merrimack; Research grant/Funding (institution): Biomarin; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Abraxis BioScience; Research grant/Funding (institution): AB Science; Research grant/Funding (institution): Asana BioSciences; Research grant/Funding (institution): Exelixis, Research grant/Funding (institution): ImClone Systems, Research grant/Funding (institution): LEO Pharma; Research grant/Funding (institution): Millennium; Advisory/Consultancy: Merck Sharp and Dohme; Advisory/Consultancy: AstraZeneca. V.C. Dieras: Honoraria (self), Advisory/Consultancy: Roche/Genentech, Pfizer, Lilly, Novartis, Daiichi Sankyo, AstraZeneca, AbbVie, Seattle Genetics, Odonate, MSD. H. Iwata: Honoraria (self), Advisory/Consultancy: Chugai; Honoraria (self), Advisory/Consultancy: Novartis, AstraZeneca, Pfizer, Lilly, Daiichi-Sankyo, Eisai, Kyowa Kirin; Non-remunerated activity/ies: MSD, Bayer, BI, Nihon, Kayaku, Sanofi. S. Loi: Research grant/Funding (institution), Non-remunerated activity/ies: Novartis, BMS, Roche-Genentech, Merck; Research grant/Funding (institution): Puma, Eli Lilly, Pfizer; Unpaid consultant: Seattle Genetics; Unpaid consultant: Pfizer; Unpaid consultant: Novartis; Unpaid consultant: BMS; Unpaid consultant: AstraZeneca; Unpaid consultant: Roche/Genentech; Advisory/Consultancy (institution): Aduro Biotechnology. H.S. Rugo: Research grant/Funding (institution): Pfizer, Novartis, Lilly, Genentech/Roche, Merck, OBI, Eisai, Plexxikon, Immunomedics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Macrogeneics, Daiichi; Travel/Accommodation/Expenses: Puma, Mylan, Genentech/Roche, Novartis, Pfizer; Honoraria (self): Celltrion. A. Schneeweiss: Research grant/Funding (institution): Celgene, Roche, AbbVie, Molecular Partner; Advisory/Consultancy: Roche AstraZeneca; Travel/Accommodation/Expenses: Celgene, Roche, Pfizer; Honoraria (self): Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly. E.P. Winer: Honoraria (self): Lilly, Genentech, Infinite MD, Carrick Therapeutics, GSK, Jounce, Genomic HEalth, Merck, Seattle Genetics; Honoraria (self), Leadership role: Leap. S. Patel: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche. V. Henschel: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche. A. Swat: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche. M. Kaul: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche. L. Molinero: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche. S.Y. Chui: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. P. Schmid: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Spouse/Financial dependant, spouse -- consulting for Genentech: Roche; Honoraria (self): Medscape; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self): GI Therapeutics; Honoraria (self): Health Interactions; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Merck; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bayer; Advisory/Consultancy: EISAI; Advisory/Consultancy: Celegence; Advisory/Consultancy: Puma; Research grant/Funding (institution), Spouse/Financial dependant, spouse -- consulting for Genentech: Genentech; Research grant/Funding (institution): Oncogenex.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.